Royal Marsden NHS Foundation Trust

A three-drug therapy (inavolisib, palbociclib, and fulvestrant) for PIK3CA-mutated HR+/HER2- breast cancer showed a 15-month delay in disease progression vs. 7.3 months with placebo, potentially doubling progression-free survival. The study, INAVO120, involved 325 patients across 28 countries, with 46.2% showing no progression after 18 months in the treatment group compared to 21.1% in the placebo group.

A trial found that a combination of three drugs can double survival time for patients with incurable breast cancer, potentially transforming outcomes for many of the 61,000 UK women with advanced breast cancer.

A three-drug therapy for advanced breast cancer potentially doubles time without disease progression, according to a trial published in The New England Journal of Medicine. The combination, including palbociclib, inavolisib, and fulvestrant, delayed progression by 15 months compared to 7.3 months with a placebo. This breakthrough could be transformative for HR+/HER2- breast cancer patients.

IMU Biosciences joins MANIFEST, a UK-wide platform to understand immunotherapy response and side effects in cancer patients, funded by £9 million from the UK government and £12.9 million from industry partners. IMU will analyze blood samples using AI-powered immune profiling to develop predictive biomarkers and improve treatment outcomes, initially focusing on melanoma, renal cell carcinoma, bladder cancer, and triple-negative breast cancer.

New UK-created cancer therapies to be trialled, benefiting NHS patients through partnerships with pharmaceutical companies and universities. Innovations include AI for early cancer detection and flexible medical scanners, aiming to transform treatment and boost the UK's life sciences industry.

Elaine Sleigh, a breast cancer patient, saw her tumours decrease by 65% due to research at The Christie NHS Foundation Trust. After initial treatment, she joined a trial for a new blood test to detect cancer cell DNA in the bloodstream. When cancer recurred, she participated in the PETRA trial, receiving a combination of targeted chemotherapy and an experimental drug, AZD5305, which is a PARP inhibitor. Elaine's condition improved, and she attributes her progress to the trials and positive attitude.

IMU Biosciences joins MANIFEST, a UK-wide consortium to understand cancer immunotherapy response and side effects, funded by £9 million from the UK government and £12.9 million from industry partners. The four-year project aims to develop predictive biomarkers for patient response, resistance, and immune-related adverse events, focusing on melanoma, renal cell carcinoma, bladder cancer, and triple-negative breast cancer.

IMU Biosciences joins MANIFEST, a UK consortium aiming to enhance cancer immunotherapies' safety and efficacy, using AI-driven immune profiling to analyze patient responses and develop predictive biomarkers.

NHS cancer patients to benefit from new partnerships with pharmaceutical companies and universities, aiming to spot cancer sooner through trials of AI and other technologies. This initiative could transform treatment and launch globally significant Medtech products, supported by £118 million in UKRI funding for five new health tech hubs. The UK's life sciences industry, already contributing £108 billion to the economy, is set to drive further investment and innovation in cancer treatment and diagnostics.